#EnvisionYourFuture | Senior Director/Vice President, Global Quality Assurance #EYPT is hiring an experienced Senior Director/Vice President of Global Quality Assurance to oversee all global quality related operations and scale our U.S. GMP Quality Operations organization to new heights. Are you a strategic thinker ready to make an impact? #ApplyToday to join our patient-centric, fast-growing biopharmaceutical company! #Careers #Hybrid https://lnkd.in/gdFCvXZJ David V.
EyePoint
Biotechnology Research
Watertown, MA 15,861 followers
Committed to developing innovative therapeutics to improve the lives of people with serious retinal diseases.
About us
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. Our lead product candidate is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining a selective and patent-protected tyrosine kinase inhibitor in next-generation bioerodible technology. Supported by robust safety and efficacy data to date, we are presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, with topline data anticipated in 2026. We have also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD the leading cause of vision loss among people 50 years of age and older in the United States. We are committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. Driven by our core values – Transformational Innovation, Unwavering Integrity, Compassionate Excellence, and Inclusive Collaboration, our team is dedicated to achieving our shared vision for the future and bettering the lives of patients, caregivers and healthcare professionals. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. Learn more: https://eyepointpharma.com/
- Website
-
http://www.eyepointpharma.com
External link for EyePoint
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Type
- Public Company
- Specialties
- Ophthalmology, Optometry, Eye Disease, Retinal Disease, Diabetic Macular Edema (DME), and Wet Age-Related Macular Degeneration (AMD)
Locations
-
Get directions
480 Pleasant St., Suite B300
Watertown, MA 02472, US
Employees at EyePoint
Updates
-
On the horizon: We will be participating in the H.C. Wainwright & Co., LLC Virtual Conference on August 13, highlighting momentum in our pivotal Phase 3 wet AMD program and our continued commitment to advancing retinal innovation. Learn more: https://lnkd.in/gpZ4ESn9
-
-
#InvestorNews: #EYPT reports Q2 2025 financial results & highlights recent corporate developments. Learn more about our latest progress, including next steps for our two Phase 3 pivotal wet AMD clinical trials here: https://lnkd.in/gs8ZkjFf
-
-
Today, we’re excited to spotlight Prethy Rao, M.D., MPH, as our first featured #EyesOnTheRise Retina Specialist. Check out more below as she shares personal experiences on her hard work on the path to success in the #Retina field.
-
Today, we celebrate the incredible 2025 summer interns who bring fresh ideas, hard work, and enthusiasm to our teams across several departments. Your dedication, passion, and drive are truly inspiring as we all work to develop therapeutics to improve the lives of patients with serious retinal diseases. #NationalInternDay #FormulateYourFuture
-
-
We are proud to reiterate, our second Pivotal Phase 3 LUCIA trial for wet AMD has fully enrolled and randomized over 400 patients in 7️⃣ months! This milestone was accomplished by a diligent, dedicated and hard-working team of investigators and study coordinators with an unwavering commitment to patients. From everyone at EyePoint, thank you!
-
-
ANNOUNCING! 📨One of the fastest enrolling Phase 3 pivotal programs for wet AMD ☑️ 400+ patients enrolled & randomized in 7 months for LUCIA ❗800+ total patients enrolled & randomized across LUGANO & LUCIA 📈 Topline LUGANO data expected mid-2026 with LUCIA to closely follow 👉 Learn more about our latest milestone here: https://lnkd.in/gUH3Gjrd
-
Our team is off to sunny California to present 3 posters at this year’s ASRS – American Society of Retina Specialists Annual Meeting in Long Beach. Don’t miss learning more about: 1. Treatment Burden in Wet Age-Related Macular Degeneration in the DAVIO 2 Phase 2 Clinical Trial 2. Vision Outcomes from the DAVIO 2 Trial 3. VERONA: End-of-Study Results from a Phase 2 Trial
-
-
🏆 Big congratulations to our CEO, Jay S. Duker, M.D. and his tennis partner Michelle Liang, M.D., who made the finals at this weekend's Sippican Tennis Club’s Mixed Member-Guest Tournament in Marion, Massachusetts! Jay humbly credits Michelle for carrying the team, saying: “I applied a lesson I’ve learned guiding EyePoint to strong execution — surround yourself with great teammates. Michelle isn’t just an exceptional retinal surgeon at Tufts Medicine, she’s also a phenomenal tennis player.” Way to go, team!
-
-
“I always say it's very easy to identify problems. It's not so easy to come up with the solutions, or even the right solution. And that's really what we try to do on a daily basis here.” - Jay S. Duker, M.D. Hear more below from Jay, #EYPT President and CEO, on the innovation and dedication our team upholds every day at EyePoint.